{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:27:22Z","timestamp":1790713642957,"version":"4.1.0"},"reference-count":147,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T00:00:00Z","timestamp":1720396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>The emergence of sustained neuropsychiatric symptoms (NPS) among non-demented individuals in later life, defined as mild behavioral impairment (MBI), is linked to a higher risk of cognitive decline. However, the underlying pathophysiological mechanisms remain largely unexplored. A growing body of evidence has shown that MBI is associated with alterations in structural and functional neuroimaging studies, higher genetic predisposition to clinical diagnosis of Alzheimer\u2019s disease (AD), as well as amyloid and tau pathology assessed in the blood, cerebrospinal fluid, positron-emission tomography (PET) imaging and neuropathological examination. These findings shed more light on the MBI-related potential neurobiological mechanisms, paving the way for the development of targeted pharmacological approaches. In this review, we aim to discuss the available clinical evidence on the role of amyloid and tau pathology in MBI and the potential underlying pathophysiological mechanisms. Dysregulation of the hypothalamic\u2013pituitary\u2013adrenal (HPA) axis, disruption of neurotrophic factors, such as the brain-derived neurotrophic factor (BDNF), abnormal neuroinflammatory responses including the kynurenine pathway, dysregulation of transforming growth factor beta (TGF-\u03b21), epigenetic alterations including micro-RNA (miR)-451a and miR-455-3p, synaptic dysfunction, imbalance in neurotransmitters including acetylcholine, dopamine, serotonin, gamma-aminobutyric acid (GABA) and norepinephrine, as well as altered locus coeruleus (LC) integrity are some of the potential mechanisms connecting MBI with amyloid and tau pathology. The elucidation of the underlying neurobiology of MBI would facilitate the design and efficacy of relative clinical trials, especially towards amyloid- or tau-related pathways. In addition, we provide insights for future research into our deeper understanding of its underlying pathophysiology of MBI, and discuss relative therapeutic implications.<\/jats:p>","DOI":"10.3390\/cells13131164","type":"journal-article","created":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T12:21:03Z","timestamp":1720441263000},"page":"1164","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Unraveling the Potential Underlying Mechanisms of Mild Behavioral Impairment: Focusing on Amyloid and Tau Pathology"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1426-3384","authenticated-orcid":false,"given":"Efthalia","family":"Angelopoulou","sequence":"first","affiliation":[{"name":"1st Department of Neurology, Aiginition University Hospital, National and Kapodistrian University of Athens, Vasilissis Sofias Street 72-74, 11528 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3006-8711","authenticated-orcid":false,"given":"Anastasia","family":"Bougea","sequence":"additional","affiliation":[{"name":"1st Department of Neurology, Aiginition University Hospital, National and Kapodistrian University of Athens, Vasilissis Sofias Street 72-74, 11528 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandros","family":"Hatzimanolis","sequence":"additional","affiliation":[{"name":"1st Department of Psychiatry, Aiginition University Hospital, National and Kapodistrian University of Athens, Vasilissis Sofias Street 72-74, 11528 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Scarmeas","sequence":"additional","affiliation":[{"name":"1st Department of Neurology, Aiginition University Hospital, National and Kapodistrian University of Athens, Vasilissis Sofias Street 72-74, 11528 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8863-3635","authenticated-orcid":false,"given":"Sokratis G.","family":"Papageorgiou","sequence":"additional","affiliation":[{"name":"1st Department of Neurology, Aiginition University Hospital, National and Kapodistrian University of Athens, Vasilissis Sofias Street 72-74, 11528 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/alzrt143","article-title":"Dementia: A global health priority\u2014Highlights from an ADI and World Health Organization report","volume":"4","author":"Wortmann","year":"2012","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"53","DOI":"10.5535\/arm.22027","article-title":"Dementia Epidemiology Fact Sheet 2022","volume":"46","author":"Shin","year":"2022","journal-title":"Ann. Rehabil. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s10072-017-3206-0","article-title":"The diagnosis of dementias: A practical tool not to miss rare causes","volume":"39","author":"Ferrari","year":"2018","journal-title":"Neurol. Sci."},{"key":"ref_4","first-page":"43","article-title":"Alzheimer\u2019s Disease Puzzle: Delving into Pathogenesis Hypotheses","volume":"15","author":"Nasb","year":"2024","journal-title":"Aging Dis."},{"key":"ref_5","first-page":"1","article-title":"Subjective cognitive decline, mild cognitive impairment, and dementia\u2014Syndromic approach: Recommendations of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology","volume":"16","author":"Smid","year":"2022","journal-title":"Dement. Neuropsychol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13024-020-00391-7","article-title":"Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer\u2019s disease","volume":"15","author":"Guo","year":"2020","journal-title":"Mol. Neurodegener."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1093\/brain\/awq383","article-title":"Independent contribution of temporal \u03b2-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer\u2019s disease","volume":"134","author":"Villemagne","year":"2011","journal-title":"Brain J. Neurol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1474-4422(13)70044-9","article-title":"Amyloid \u03b2 deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer\u2019s disease: A prospective cohort study","volume":"12","author":"Villemagne","year":"2013","journal-title":"Lancet Neurol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13024-023-00631-6","article-title":"Optimizing detection of Alzheimer\u2019s disease in mild cognitive impairment: A 4-year biomarker study of mild behavioral impairment in ADNI and MEMENTO","volume":"18","author":"Ismail","year":"2023","journal-title":"Mol. Neurodegener."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jalz.2015.12.003","article-title":"Why has therapy development for dementia failed in the last two decades?","volume":"12","author":"Gauthier","year":"2016","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_11","first-page":"123","article-title":"Alzheimer\u2019s Disease\u2014Why We Need Early Diagnosis","volume":"9","author":"Rasmussen","year":"2019","journal-title":"Degener. Neurol. Neuromuscul. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Pless, A., Ware, D., Saggu, S., Rehman, H., Morgan, J., and Wang, Q. (2023). Understanding neuropsychiatric symptoms in Alzheimer\u2019s disease: Challenges and advances in diagnosis and treatment. Front. Neurosci., 17.","DOI":"10.3389\/fnins.2023.1263771"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1159\/000339954","article-title":"Delusions increase functional impairment in Alzheimer\u2019s disease","volume":"33","author":"Fischer","year":"2012","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/gps.2550","article-title":"Neuropsychiatric symptoms and quality of life in patients with very mild and mild Alzheimer\u2019s disease","volume":"26","author":"Karttunen","year":"2011","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1532-5415.2011.03314.x","article-title":"Neuropsychiatric symptoms and the risk of institutionalization and death: The aging, demographics, and memory study","volume":"59","author":"Okura","year":"2011","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_16","first-page":"333","article-title":"Time course of neuropsychiatric symptoms and cognitive diagnosis in National Alzheimer\u2019s Coordinating Centers volunteers","volume":"11","author":"Wise","year":"2019","journal-title":"Alzheimer\u2019s Dement. Diagn. Assess. Dis. Monit."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1017\/S1041610218001138","article-title":"Depressive symptoms in relation to clinical symptom onset of mild cognitive impairment","volume":"31","author":"Chan","year":"2019","journal-title":"Int. Psychogeriatr."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1001\/jamapsychiatry.2017.0660","article-title":"Trajectories of Depressive Symptoms Before Diagnosis of Dementia: A 28-Year Follow-up Study","volume":"74","author":"Dugravot","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jalz.2015.05.017","article-title":"Neuropsychiatric symptoms as early manifestations of emergent dementia: Provisional diagnostic criteria for mild behavioral impairment","volume":"12","author":"Ismail","year":"2016","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1002\/alz.12519","article-title":"Mild behavioral impairment is associated with progression to Alzheimer\u2019s disease: A clinicopathological study","volume":"18","author":"Ruthirakuhan","year":"2022","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Angelopoulou, E., Koros, C., Hatzimanolis, A., Stefanis, L., Scarmeas, N., and Papageorgiou, S.G. (2024). Exploring the Genetic Landscape of Mild Behavioral Impairment as an Early Marker of Cognitive Decline: An Updated Review Focusing on Alzheimer\u2019s Disease. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25052645"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13195-021-00949-7","article-title":"Mild behavioral impairment: Measurement and clinical correlates of a novel marker of preclinical Alzheimer\u2019s disease","volume":"14","author":"Creese","year":"2022","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Jin, P., Xu, J., Liao, Z., Zhang, Y., Wang, Y., Sun, W., and Yu, E. (2023). A review of current evidence for mild behavioral impairment as an early potential novel marker of Alzheimer\u2019s disease. Front. Psychiatry, 14.","DOI":"10.3389\/fpsyt.2023.1099333"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40035-021-00236-3","article-title":"Associations of AT(N) biomarkers with neuropsychiatric symptoms in preclinical Alzheimer\u2019s disease and cognitively unimpaired individuals","volume":"10","author":"Ng","year":"2021","journal-title":"Transl. Neurodegener."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"929","DOI":"10.3233\/JAD-160979","article-title":"The Mild Behavioral Impairment Checklist (MBI-C): A Rating Scale for Neuropsychiatric Symptoms in Pre-Dementia Populations","volume":"56","author":"Ismail","year":"2017","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3233\/JAD-201184","article-title":"Mild Behavioral Impairment and Subjective Cognitive Decline Predict Cognitive and Functional Decline","volume":"80","author":"Ismail","year":"2021","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1017\/S104161021700151X","article-title":"Prevalence of mild behavioral impairment in mild cognitive impairment and subjective cognitive decline, and its association with caregiver burden","volume":"30","author":"Sheikh","year":"2018","journal-title":"Int. Psychogeriatr."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1177\/08919887211016068","article-title":"Plasma \u03b2-Amyloid in Mild Behavioural Impairment\u2014Neuropsychiatric Symptoms on the Alzheimer\u2019s Continuum","volume":"35","author":"Miao","year":"2022","journal-title":"J. Geriatr. Psychiatry Neurol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1017\/S1041610218000698","article-title":"Assessing mild behavioral impairment with the mild behavioral impairment checklist in people with subjective cognitive decline","volume":"31","author":"Mallo","year":"2019","journal-title":"Int. Psychogeriatr."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3233\/JAD-180131","article-title":"Assessing Mild Behavioral Impairment with the Mild Behavioral Impairment-Checklist in People with Mild Cognitive Impairment","volume":"66","author":"Mallo","year":"2018","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jagp.2019.01.215","article-title":"Mild Behavioral Impairment as a Marker of Cognitive Decline in Cognitively Normal Older Adults","volume":"27","author":"Creese","year":"2019","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"5481","DOI":"10.1038\/s41380-021-01249-0","article-title":"The Amyloid-\u03b2 Pathway in Alzheimer\u2019s Disease","volume":"26","author":"Hampel","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Sehar, U., Rawat, P., Reddy, A.P., Kopel, J., and Reddy, P.H. (2022). Amyloid Beta in Aging and Alzheimer\u2019s Disease. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232112924"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Gu\u00e9nette, S., Strecker, P., and Kins, S. (2017). APP Protein Family Signaling at the Synapse: Insights from Intracellular APP-Binding Proteins. Front. Mol. Neurosci., 10.","DOI":"10.3389\/fnmol.2017.00087"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"5541","DOI":"10.2147\/IJN.S200490","article-title":"Alzheimer\u2019s disease: Pathogenesis, diagnostics, and therapeutics","volume":"14","author":"Tiwari","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Ma, C., Hong, F., and Yang, S. (2022). Amyloidosis in Alzheimer\u2019s Disease: Pathogeny, Etiology, and Related Therapeutic Directions. Molecules, 27.","DOI":"10.3390\/molecules27041210"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.2353\/ajpath.2010.100346","article-title":"A\u03b2 accelerates the spatiotemporal progression of tau pathology and augments tau amyloidosis in an Alzheimer mouse model","volume":"177","author":"Hurtado","year":"2010","journal-title":"Am. J. Pathol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13195-024-01434-7","article-title":"Cerebrospinal fluid amyloid-\u03b2 and cerebral microbleed are associated with distinct neuropsychiatric sub-syndromes in cognitively impaired patients","volume":"16","author":"Zeng","year":"2024","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.jagp.2020.01.012","article-title":"The Association between Biomarkers and Neuropsychiatric Symptoms across the Alzheimer\u2019s Disease Spectrum","volume":"28","author":"Banning","year":"2020","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1136\/jnnp-2013-306110","article-title":"Apathy correlates with prefrontal amyloid \u03b2 deposition in Alzheimer\u2019s disease","volume":"85","author":"Mori","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1177\/0891988719838627","article-title":"Association between CSF Beta-Amyloid and Apathy in Early-Stage Alzheimer Disease","volume":"32","author":"Vergallo","year":"2019","journal-title":"J. Geriatr. Psychiatry Neurol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"656","DOI":"10.2174\/156720510793611592","article-title":"Tau in Alzheimer disease and related tauopathies","volume":"7","author":"Iqbal","year":"2010","journal-title":"Curr. Alzheimer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/j.parkreldis.2015.09.020","article-title":"Tauopathies as clinicopathological entities","volume":"22","author":"Irwin","year":"2016","journal-title":"Park. Relat. Disord."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1080\/00207454.2020.1758087","article-title":"The histopathological staging of tau, but not amyloid, corresponds to antemortem cognitive status, dementia stage, functional abilities and neuropsychiatric symptoms","volume":"131","author":"Malpas","year":"2021","journal-title":"Int. J. Neurosci."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1093\/brain\/awz268","article-title":"The bivariate distribution of amyloid-\u03b2 and tau: Relationship with established neurocognitive clinical syndromes","volume":"142","author":"Jack","year":"2019","journal-title":"Brain J. Neurol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1001\/jamaneurol.2020.0989","article-title":"Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease from Other Neurodegenerative Disorders","volume":"77","author":"Leuzy","year":"2020","journal-title":"JAMA Neurol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/hbm.26043","article-title":"Tau as a biomarker of cognitive impairment and neuropsychiatric symptom in Alzheimer\u2019s disease","volume":"44","author":"Dang","year":"2023","journal-title":"Hum. Brain Mapp."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e12154","DOI":"10.1002\/trc2.12154","article-title":"Association between regional tau pathology and neuropsychiatric symptoms in aging and dementia due to Alzheimer\u2019s disease","volume":"7","author":"Tissot","year":"2021","journal-title":"Alzheimer\u2019s Dement. Transl. Res. Clin. Interv."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1159\/000137671","article-title":"Neuropsychiatric correlates of cerebrospinal fluid biomarkers in Alzheimer\u2019s disease","volume":"25","author":"Skogseth","year":"2008","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"759","DOI":"10.3233\/JAD-131166","article-title":"Hyperphosphorylated tau is elevated in Alzheimer\u2019s disease with psychosis","volume":"39","author":"Murray","year":"2014","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.biopsych.2020.01.023","article-title":"Amyloid and Tau Pathology Associations with Personality Traits, Neuropsychiatric Symptoms, and Cognitive Lifestyle in the Preclinical Phases of Sporadic and Autosomal Dominant Alzheimer\u2019s Disease","volume":"89","author":"Morris","year":"2021","journal-title":"Biol. Psychiatry"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/gps.5459","article-title":"Relationship between neuropsychiatric symptoms and Alzheimer\u2019s disease pathology: An in vivo positron emission tomography study","volume":"36","author":"Yasuno","year":"2021","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41398-021-01675-2","article-title":"Mild behavioral impairment correlates of cognitive impairments in older adults without dementia: Mediation by amyloid pathology","volume":"11","author":"Sun","year":"2021","journal-title":"Transl. Psychiatry"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/alz.12007","article-title":"Mild behavioral impairment is associated with \u03b2-amyloid but not tau or neurodegeneration in cognitively intact elderly individuals","volume":"16","author":"Lussier","year":"2020","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1212\/WNL.58.12.1791","article-title":"Phases of A\u03b2-deposition in the human brain and its relevance for the development of AD","volume":"58","author":"Thal","year":"2002","journal-title":"Neurology"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.jalz.2018.04.011","article-title":"PET staging of amyloidosis using striatum","volume":"14","author":"Hanseeuw","year":"2018","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.3233\/JAD-215267","article-title":"Association between Late-Life Neuropsychiatric Symptoms and Cognitive Decline in Relation to White Matter Hyperintensities and Amyloid Burden","volume":"86","author":"Chan","year":"2022","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1176\/appi.ajp.2017.17040442","article-title":"Longitudinal Association of Amyloid Beta and Anxious-Depressive Symptoms in Cognitively Normal Older Adults","volume":"175","author":"Donovan","year":"2018","journal-title":"Am. J. Psychiatry"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jad.2017.12.101","article-title":"Amyloid burden and incident depressive symptoms in preclinical Alzheimer\u2019s disease","volume":"229","author":"Perin","year":"2018","journal-title":"J. Affect. Disord."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e683","DOI":"10.1212\/WNL.0000000000201517","article-title":"Plasma Phosphorylated Tau at Threonine 181 and Neuropsychiatric Symptoms in Preclinical and Prodromal Alzheimer Disease","volume":"100","author":"Ghahremani","year":"2023","journal-title":"Neurology"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/s41386-022-01293-6","article-title":"Association of locus coeruleus integrity with Braak stage and neuropsychiatric symptom severity in Alzheimer\u2019s disease","volume":"47","author":"Cassidy","year":"2022","journal-title":"Neuropsychopharmacology"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41398-021-01206-z","article-title":"Mild behavioral impairment and its relation to tau pathology in preclinical Alzheimer\u2019s disease","volume":"11","author":"Johansson","year":"2021","journal-title":"Transl. Psychiatry"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e5993","DOI":"10.1002\/gps.5993","article-title":"Contribution of amyloid and putative Lewy body pathologies in neuropsychiatric symptoms","volume":"38","author":"Matsuoka","year":"2023","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.neurobiolaging.2024.02.006","article-title":"Tau-PET in early cortical Alzheimer brain regions in relation to mild behavioral impairment in older adults with either normal cognition or mild cognitive impairment","volume":"138","author":"Naude","year":"2024","journal-title":"Neurobiol. Aging"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/s41398-021-01653-8","article-title":"Prefrontal A\u03b2 pathology influencing the pathway from apathy to cognitive decline in non-dementia elderly","volume":"11","author":"Sun","year":"2021","journal-title":"Transl. Psychiatry"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.jalz.2019.03.009","article-title":"Plasma amyloid \u03b2 40\/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer\u2019s disease","volume":"15","author":"Vergallo","year":"2019","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/WAD.0000000000000284","article-title":"Examining the Complicated Relationship between Depressive Symptoms and Cognitive Impairment in Preclinical Alzheimer Disease","volume":"33","author":"Javaherian","year":"2019","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e198964","DOI":"10.1001\/jamanetworkopen.2019.8964","article-title":"Longitudinal Association of Depression Symptoms with Cognition and Cortical Amyloid Among Community-Dwelling Older Adults","volume":"2","author":"Gatchel","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1038\/s41380-018-0323-y","article-title":"Correction: Association of anxiety with subcortical amyloidosis in cognitively normal older adults","volume":"25","author":"Hanseeuw","year":"2020","journal-title":"Mol. Psychiatry"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3233\/JAD-180688","article-title":"Neuropathologic Correlates of Psychiatric Symptoms in Alzheimer\u2019s Disease","volume":"66","author":"Ehrenberg","year":"2018","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"975","DOI":"10.3233\/JAD-170001","article-title":"Depressive Symptoms and Tau Accumulation in the Inferior Temporal Lobe and Entorhinal Cortex in Cognitively Normal Older Adults: A Pilot Study","volume":"59","author":"Gatchel","year":"2017","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.jagp.2016.04.004","article-title":"Mood Changes in Cognitively Normal Older Adults are Linked to Alzheimer Disease Biomarker Levels","volume":"24","author":"Babulal","year":"2016","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1017\/S0033291712001870","article-title":"Anxiety is related to Alzheimer cerebrospinal fluid markers in subjects with mild cognitive impairment","volume":"43","author":"Ramakers","year":"2013","journal-title":"Psychol. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","article-title":"Plasma P-tau181 in Alzheimer\u2019s disease: Relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer\u2019s dementia","volume":"26","author":"Janelidze","year":"2020","journal-title":"Nat. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41380-020-00923-z","article-title":"Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer\u2019s Disease Neuroimaging Initiative","volume":"26","author":"Karikari","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jalz.2018.02.013","article-title":"Plasma phospho-tau181 increases with Alzheimer\u2019s disease clinical severity and is associated with tau- and amyloid-positron emission tomography","volume":"14","author":"Mielke","year":"2018","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Sakakibara, Y., Sekiya, M., Saito, T., Saido, T.C., and Iijima, K.M. (2018). Cognitive and emotional alterations in App knock-in mouse models of A\u03b2 amyloidosis. BMC Neurosci., 19.","DOI":"10.1186\/s12868-018-0446-8"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.bbr.2017.11.017","article-title":"Subtle behavioral changes and increased prefrontal-hippocampal network synchronicity in APP(NL-G-F) mice before prominent plaque deposition","volume":"364","author":"Shah","year":"2019","journal-title":"Behav. Brain Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1111\/brv.12750","article-title":"Chronic stress and Alzheimer\u2019s disease: The interplay between the hypothalamic-pituitary-adrenal axis, genetics and microglia","volume":"96","author":"Porter","year":"2021","journal-title":"Biol. Rev. Camb. Philos. Soc."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1016\/j.neurobiolaging.2012.01.002","article-title":"Central CRF system perturbation in an Alzheimer\u2019s disease knockin mouse model","volume":"33","author":"Guo","year":"2012","journal-title":"Neurobiol. Aging"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.neurobiolaging.2012.11.015","article-title":"Deregulation of hypothalamic-pituitary-adrenal axis functions in an Alzheimer\u2019s disease rat model","volume":"34","author":"Brureau","year":"2013","journal-title":"Neurobiol. Aging"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.biopsych.2009.06.015","article-title":"Intraneuronal \u03b2-amyloid accumulation in the amygdala enhances fear and anxiety in Alzheimer\u2019s disease transgenic mice","volume":"67","author":"Valero","year":"2010","journal-title":"Biol. Psychiatry"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.phrs.2018.02.007","article-title":"Neurobiological links between depression and AD: The role of TGF-\u03b21 signaling as a new pharmacological target","volume":"130","author":"Caraci","year":"2018","journal-title":"Pharmacol. Res."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Cavaleri, D., Moretti, F., Bartoccetti, A., Mauro, S., Crocamo, C., Carr\u00e0, G., and Bartoli, F. (2023). The role of BDNF in major depressive disorder, related clinical features, and antidepressant treatment: Insight from meta-analyses. Neurosci. Biobehav. Rev., 149.","DOI":"10.1016\/j.neubiorev.2023.105159"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1601-183X.2007.00378.x","article-title":"Neurotrophic factors in Alzheimer\u2019s disease: Role of axonal transport","volume":"7","author":"Schindowski","year":"2008","journal-title":"Genes Brain Behav."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40035-022-00279-0","article-title":"Brain-derived neurotrophic factor in Alzheimer\u2019s disease and its pharmaceutical potential","volume":"11","author":"Gao","year":"2022","journal-title":"Transl. Neurodegener."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"523","DOI":"10.3233\/JAD-2011-110113","article-title":"BDNF gene polymorphisms are associated with Alzheimer\u2019s disease-related depression and antidepressant response","volume":"26","author":"Zhang","year":"2011","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1111\/j.1460-9568.2005.04290.x","article-title":"Brain-derived neurotrophic factor induces a rapid dephosphorylation of tau protein through a PI-3 Kinase signalling mechanism","volume":"22","author":"Elliott","year":"2005","journal-title":"Eur. J. Neurosci."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1523\/JNEUROSCI.5053-06.2007","article-title":"Oligomeric amyloid decreases basal levels of brain-derived neurotrophic factor (BDNF) mRNA via specific downregulation of BDNF transcripts IV and V in differentiated human neuroblastoma cells","volume":"27","author":"Garzon","year":"2007","journal-title":"J. Neurosci."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"204","DOI":"10.2478\/v10039-010-0023-6","article-title":"Kynurenine and its metabolites in Alzheimer\u2019s disease patients","volume":"55","author":"Gulaj","year":"2010","journal-title":"Adv. Med. Sci."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s007020050029","article-title":"Tryptophan degradation and immune activation in Alzheimer\u2019s disease","volume":"107","author":"Widner","year":"2000","journal-title":"J. Neural Transm."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.bbi.2021.03.019","article-title":"Inflammation, negative affect, and amyloid burden in Alzheimer\u2019s disease: Insights from the kynurenine pathway","volume":"95","author":"Willette","year":"2021","journal-title":"Brain Behav. Immun."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1001\/archneur.57.8.1153","article-title":"Cytokine gene expression as a function of the clinical progression of Alzheimer disease dementia","volume":"57","author":"Luterman","year":"2000","journal-title":"Arch. Neurol."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Caraci, F., Tascedda, F., Merlo, S., Benatti, C., Spampinato, S.F., Munaf\u00f2, A., Leggio, G.M., Nicoletti, F., Brunello, N., and Drago, F. (2016). Fluoxetine Prevents A\u03b21\u201342-Induced Toxicity via a Paracrine Signaling Mediated by Transforming-Growth-Factor-\u03b21. Front. Pharmacol., 7.","DOI":"10.3389\/fphar.2016.00389"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"6790","DOI":"10.1007\/s12035-022-03012-0","article-title":"Plasma Exo-miRNAs Correlated with AD-Related Factors of Chinese Individuals Involved in A\u03b2 Accumulation and Cognition Decline","volume":"59","author":"Wang","year":"2022","journal-title":"Mol. Neurobiol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.7150\/thno.81826","article-title":"Decreased miR-451a in cerebrospinal fluid, a marker for both cognitive impairment and depressive symptoms in Alzheimer\u2019s disease","volume":"13","author":"Feng","year":"2023","journal-title":"Theranostics"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Swingler, T.E., Niu, L., Pontifex, M.G., Vauzour, D., and Clark, I.M. (2022). The microRNA-455 Null Mouse Has Memory Deficit and Increased Anxiety, Targeting Key Genes Involved in Alzheimer\u2019s Disease. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23010554"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/cns.12484","article-title":"Role of Donepezil in the Management of Neuropsychiatric Symptoms in Alzheimer\u2019s Disease and Dementia with Lewy Bodies","volume":"22","author":"Cummings","year":"2016","journal-title":"CNS Neurosci. Ther."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Fagiani, F., Lanni, C., Racchi, M., and Govoni, S. (2021). (Dys)regulation of Synaptic Activity and Neurotransmitter Release by \u03b2-Amyloid: A Look Beyond Alzheimer\u2019s Disease Pathogenesis. Front. Mol. Neurosci., 14.","DOI":"10.3389\/fnmol.2021.635880"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/sj.npp.1301485","article-title":"Acute \u03b2-amyloid administration disrupts the cholinergic control of dopamine release in the nucleus accumbens","volume":"33","author":"Preda","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jalz.2016.06.2362","article-title":"Locus coeruleus volume and cell population changes during Alzheimer\u2019s disease progression: A stereological study in human postmortem brains with potential implication for early-stage biomarker discovery","volume":"13","author":"Theofilas","year":"2017","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Gannon, M., Che, P., Chen, Y., Jiao, K., Roberson, E.D., and Wang, Q. (2015). Noradrenergic dysfunction in Alzheimer\u2019s disease. Front. Neurosci., 9.","DOI":"10.3389\/fnins.2015.00220"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1176\/ajp.154.1.25","article-title":"Effects of Alzheimer\u2019s disease severity on cerebrospinal fluid norepinephrine concentration","volume":"154","author":"Elrod","year":"1997","journal-title":"Am. J. Psychiatry"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/s41380-019-0437-x","article-title":"Alzheimer\u2019s disease pathology: Pathways between central norepinephrine activity, memory, and neuropsychiatric symptoms","volume":"26","author":"Jacobs","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Yang, Y., and Wang, J.-Z. (2017). From Structure to Behavior in Basolateral Amygdala-Hippocampus Circuits. Front. Neural Circuits, 11.","DOI":"10.3389\/fncir.2017.00086"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"10019","DOI":"10.1523\/JNEUROSCI.1267-18.2018","article-title":"Specificity of Primate Amygdalar Pathways to Hippocampus","volume":"38","author":"Wang","year":"2018","journal-title":"J. Neurosci."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Sawant, N., Kshirsagar, S., Reddy, P.H., and Reddy, A.P. (2024). Protective effects of SSRI, Citalopram in mutant APP and mutant Tau expressed dorsal raphe neurons in Alzheimer\u2019s disease. Biochim. Biophys. Acta Mol. Basis Dis., 1870.","DOI":"10.1016\/j.bbadis.2023.166942"},{"key":"ref_109","first-page":"236re234","article-title":"An antidepressant decreases CSF A\u03b2 production in healthy individuals and in transgenic AD mice","volume":"6","author":"Sheline","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1093\/hmg\/ddab054","article-title":"Protective effects of antidepressant citalopram against abnormal APP processing and amyloid beta-induced mitochondrial dynamics, biogenesis, mitophagy and synaptic toxicities in Alzheimer\u2019s disease","volume":"30","author":"Reddy","year":"2021","journal-title":"Hum. Mol. Genet."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1111\/jnc.15260","article-title":"Pimavanserin, a 5HT2A receptor inverse agonist, rapidly suppresses A\u03b2 production and related pathology in a mouse model of Alzheimer\u2019s disease","volume":"156","author":"Yuede","year":"2021","journal-title":"J. Neurochem."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/JCP.0b013e31802e0002","article-title":"Does fluoxetine have any effect on the cognition of patients with mild cognitive impairment? A double-blind, placebo-controlled, clinical trial","volume":"27","author":"Mowla","year":"2007","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1176\/appi.ajp.2017.17040404","article-title":"Impact of SSRI Therapy on Risk of Conversion from Mild Cognitive Impairment to Alzheimer\u2019s Dementia in Individuals with Previous Depression","volume":"175","author":"Bartels","year":"2018","journal-title":"Am. J. Psychiatry"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1097\/JGP.0b013e3181ab8c61","article-title":"Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression","volume":"17","author":"Wang","year":"2009","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1136\/jnnp-2022-329136","article-title":"Cognitive and neuropsychiatric effects of noradrenergic treatment in Alzheimer\u2019s disease: Systematic review and meta-analysis","volume":"93","author":"David","year":"2022","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1212\/01.WNL.0000129990.32253.7B","article-title":"The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease","volume":"63","author":"Holmes","year":"2004","journal-title":"Neurology"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/01.JGP.0000221293.91312.d3","article-title":"Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders","volume":"14","author":"Cummings","year":"2006","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/gps.1325","article-title":"Efficacy and safety of donepezil in patients with more severe Alzheimer\u2019s disease: A subgroup analysis from a randomized, placebo-controlled trial","volume":"20","author":"Feldman","year":"2005","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.brainresbull.2018.01.001","article-title":"ATP-sensitive potassium-channel inhibitor glibenclamide attenuates HPA axis hyperactivity, depression- and anxiety-related symptoms in a rat model of Alzheimer\u2019s disease","volume":"137","author":"Esmaeili","year":"2018","journal-title":"Brain Res. Bull."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"170102","DOI":"10.1016\/j.peptides.2019.170102","article-title":"Anxiolytic impact of Apelin-13 in a rat model of Alzheimer\u2019s disease: Involvement of glucocorticoid receptor and FKBP5","volume":"118","author":"Aminyavari","year":"2019","journal-title":"Peptides"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/s00213-018-5137-8","article-title":"Minocycline prevents the development of depression-like behavior and hippocampal inflammation in a rat model of Alzheimer\u2019s disease","volume":"236","author":"Amani","year":"2019","journal-title":"Psychopharmacology"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"e12515","DOI":"10.1111\/jpi.12515","article-title":"Melatonin induces mechanisms of brain resilience against neurodegeneration","volume":"65","author":"Corpas","year":"2018","journal-title":"J. Pineal Res."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"175821","DOI":"10.1016\/j.ejphar.2023.175821","article-title":"Nattokinase prevents \u03b2-amyloid peptide (A\u03b21\u201342) induced neuropsychiatric complications, neuroinflammation and BDNF signalling disruption in mice","volume":"952","author":"Naik","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Sin, Y.Y., Cameron, R.T., Schepers, M., MacLeod, R., Wright, T.A., Paes, D., van den Hove, D., Willems, E., Vanmierlo, T., and Prickaerts, J. (2024). Beta-amyloid interacts with and activates the long-form phosphodiesterase PDE4D5 in neuronal cells to reduce cAMP availability. FEBS Lett.","DOI":"10.1002\/1873-3468.14902"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1093\/ijnp\/pyad042","article-title":"Rolipram Ameliorates Memory Deficits and Depression-Like Behavior in APP\/PS1\/tau Triple Transgenic Mice: Involvement of Neuroinflammation and Apoptosis via cAMP Signaling","volume":"26","author":"Cong","year":"2023","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Xu, Y., Zhu, N., Xu, W., Ye, H., Liu, K., Wu, F., Zhang, M., Ding, Y., Zhang, C., and Zhang, H. (2018). Inhibition of Phosphodiesterase-4 Reverses A\u03b2-Induced Memory Impairment by Regulation of HPA Axis Related cAMP Signaling. Front. Aging Neurosci., 10.","DOI":"10.3389\/fnagi.2018.00204"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/ijnp\/pyaa048","article-title":"The Phosphodiesterase-4 Inhibitor Roflumilast, a Potential Treatment for the Comorbidity of Memory Loss and Depression in Alzheimer\u2019s Disease: A Preclinical Study in APP\/PS1 Transgenic Mice","volume":"23","author":"Wang","year":"2020","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Hassan, G., Kamar, S.A., Rady, H.Y., Abdelrahim, D.S., Abdel Hay Ibrahim, N.H., and Lasheen, N.N. (2024). A study of roflumilast treatment on functional and structural changes in hippocampus in depressed Adult male Wistar rats. PLoS ONE, 19.","DOI":"10.1371\/journal.pone.0296187"},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Zabot, G.C., Medeiros, E.B., Macarini, B.M.N., Peruchi, B.B., Keller, G.S., L\u00eddio, A.V., Boaventura, A., de Jesus, L.C., de Bem Silveira, G., and Silveira, P.C.L. (2024). The involvement of neuroinflammation in an animal model of dementia and depression. Prog. Neuro-Psychopharmacol. Biol. Psychiatry, 133.","DOI":"10.1016\/j.pnpbp.2024.110999"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s11357-022-00534-2","article-title":"Long-term exercise pre-training attenuates Alzheimer\u2019s disease-related pathology in a transgenic rat model of Alzheimer\u2019s disease","volume":"44","author":"Yang","year":"2022","journal-title":"GeroScience"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"112791","DOI":"10.1016\/j.bbr.2020.112791","article-title":"Prophylactic effect of physical exercise on A\u03b21\u201340-induced depressive-like behavior and gut dysfunction in mice","volume":"393","author":"Rosa","year":"2020","journal-title":"Behav. Brain Res."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"113003","DOI":"10.1016\/j.physbeh.2020.113003","article-title":"Swimming exercise improves cognitive and behavioral disorders in male NMRI mice with sporadic Alzheimer-like disease","volume":"223","author":"Bashiri","year":"2020","journal-title":"Physiol. Behav."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.psyneuen.2014.03.021","article-title":"Physical exercise neuroprotects ovariectomized 3xTg-AD mice through BDNF mechanisms","volume":"45","author":"Revilla","year":"2014","journal-title":"Psychoneuroendocrinology"},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Tolar, M., Hey, J., Power, A., and Abushakra, S. (2021). Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer\u2019s Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22126355"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"fcab147","DOI":"10.1093\/braincomms\/fcab147","article-title":"Soluble amyloid beta-containing aggregates are present throughout the brain at early stages of Alzheimer\u2019s disease","volume":"3","author":"Sideris","year":"2021","journal-title":"Brain Commun."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"e12371","DOI":"10.1002\/trc2.12371","article-title":"Functional connectivity and mild behavioral impairment in dementia-free elderly","volume":"9","author":"Ghahremani","year":"2023","journal-title":"Alzheimer\u2019s Dement. Transl. Res. Clin. Interv."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Shi, M., Chu, F., Zhu, F., and Zhu, J. (2022). Impact of Anti-amyloid-\u03b2 Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer\u2019s Disease: A Focus on Aducanumab and Lecanemab. Front. Aging Neurosci., 14.","DOI":"10.3389\/fnagi.2022.870517"},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"King, A., Bodi, I., and Troakes, C. (2020). The Neuropathological Diagnosis of Alzheimer\u2019s Disease-The Challenges of Pathological Mimics and Concomitant Pathology. Brain Sci., 10.","DOI":"10.3390\/brainsci10080479"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3233\/JAD-150606","article-title":"Lewy Bodies, Vascular Risk Factors, and Subcortical Arteriosclerotic Leukoencephalopathy, but not Alzheimer Pathology, are Associated with Development of Psychosis in Alzheimer\u2019s Disease","volume":"50","author":"Fischer","year":"2016","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_140","first-page":"100028","article-title":"White matter hyperintensities and mild behavioral impairment: Findings from the MEMENTO cohort study","volume":"2","author":"Miao","year":"2021","journal-title":"Cereb. Circ.-Cogn. Behav."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.3233\/JAD-200011","article-title":"Plasma Neurofilament Light: A Marker of Neurodegeneration in Mild Behavioral Impairment","volume":"76","author":"Naude","year":"2020","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_142","first-page":"e12164","article-title":"Genetic risk for Alzheimer\u2019s disease, cognition, and mild behavioral impairment in healthy older adults","volume":"13","author":"Creese","year":"2021","journal-title":"Alzheimer\u2019s Dement. Transl. Res. Clin. Interv."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1016\/j.neurobiolaging.2014.03.003","article-title":"Psychotic Alzheimer\u2019s disease is associated with gender-specific tau phosphorylation abnormalities","volume":"35","author":"Koppel","year":"2014","journal-title":"Neurobiol. Aging"},{"key":"ref_144","first-page":"128354","article-title":"Gender-Specific Neuroimmunoendocrine Response to Treadmill Exercise in 3xTg-AD Mice","volume":"2010","author":"Buccieri","year":"2010","journal-title":"Int. J. Alzheimer\u2019s Dis."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1093\/brain\/awx171","article-title":"Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer\u2019s disease","volume":"140","author":"Scholl","year":"2017","journal-title":"Brain J. Neurol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1111\/ene.15203","article-title":"The severity of neuropsychiatric symptoms is higher in early-onset than late-onset Alzheimer\u2019s disease","volume":"29","author":"Allen","year":"2022","journal-title":"Eur. J. Neurol."},{"key":"ref_147","first-page":"e1679","article-title":"Association of Education and Intracranial Volume with Cognitive Trajectories and Mortality Rates across the Alzheimer Disease Continuum","volume":"98","author":"Groot","year":"2022","journal-title":"Neurology"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/13\/13\/1164\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:11:51Z","timestamp":1760109111000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/13\/13\/1164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,8]]},"references-count":147,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["cells13131164"],"URL":"https:\/\/doi.org\/10.3390\/cells13131164","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,8]]}}}